RCE News: Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update - 18th Oct 2022, 11:11pm

annb0t

Top 20
Recce Pharmaceuticals

Figure 1 SARS-COV-2 50% Tissue Culture Infectious Dose (TCID50) measurement in response to treatment with R327 in Syrian golden hamsters.

Figure 2 Quantitative polymerase chain reaction (qPCR) results measuring SARS-CoV-2 genetic material in response to treatment with R327 in Syrian golden hamsters.

Highlights:

RECCE® 327 (R327) was shown to significantly reduce SARS-CoV-2 levels in hamsters, the gold-standard in COVID-19 preclinical animal models New patents lodged ...

>>> Read more: Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
 
Top Bottom